Anti-Müllerian Hormone Concentrations in Premenopausal Women and Breast Cancer Risk

Details

• Personal Author:
  Baird D ; Nichols H ; Sandler D ; Stanczyk F ; Steiner A ; Troester M ; Whitworth K
• Description:
  In laboratory models, increasing anti-Müllerian hormone (AMH) concentrations reduces breast tumor development. Human studies are lacking; one study (N=105 cases, 204 controls) with prospectively-collected serum reported the opposite - an approx. 10-fold increase in breast cancer risk comparing 4th to 1st quartile AMH levels. We investigated the relation between serum AMH levels and breast cancer risk within the Sister Study prospective cohort. We conducted a nested case-control (N=452 cases, 902 controls) study within the Sister Study cohort of 50,884 women. At enrollment, participants were ages 35-54, premenopausal, and completed questionnaires on medical and family history, lifestyle factors, and demographics. AMH (ng/ml) was measured by ultrasensitive ELISA in serum collected at enrollment and log-transformed for analysis. Multivariate conditional logistic regression was used to calculate ORs and 95% CIs to account for matching on age and enrollment year. Mean age at enrollment was 46.8 years with an average 2.9 years from blood draw to breast cancer diagnosis (SD=1.9). AMH concentrations were below the limit of detection (0.003 ng/ml) for approx. 25% of samples. Compared with samples below the LOD, women with AMH >2.84 ng/ ml (90th percentile among controls) had a 2.25-fold increase in breast cancer odds (95% CI: 1.26-4.02). For each 1-unit increase in lnAMH, overall breast cancer odds increased by 8% (OR=1.08; 95% CI: 1.02-1.15) and ER-positive, invasive disease increased by 15% (OR=1.15; 95% CI: 1.05-1.25). In our study, AMH was positively associated with breast cancer risk. Prior laboratory studies used basal-like breast cancer models such as the C3Tag mouse model or the MCF10A cell line and therefore may not generalize to more common ER-positive breast cancers. A larger study with a younger age distribution or higher proportion of basal-like tumors is needed to conclusively address possible protective effects of AMH on breast cancer. [Description provided by NIOSH]
• Subjects:
  Cohort Studies Endocrine System Occupational Health Safety
• Keywords:
  Breast Cancer Cohort Studies Heredity Hormone Activity Hormones
• Publisher:
  Society for Epidemiologic Research
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Abstract or Summary
• Place as Subject:
  Colorado ; North Carolina ; OSHA Region 4 ; OSHA Region 6 ; OSHA Region 8 ; Texas ; Utah
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  72
• NIOSHTIC Number:
  nn:20066353
• Citation:
  48th Annual Society for Epidemiologic Research (SER) Meeting, June 16-19, 2015, Denver, Colorado. Clearfield, UT: Society for Epidemiologic Research, 2015 Jun; :72
• Contact Point Address:
  Donna Nichols, University of North Carolina, Gillings School of Global Public Health
• Federal Fiscal Year:
  2015
• Performing Organization:
  University of Texas Health Science Center, Houston
• Peer Reviewed:
  False
• Start Date:
  20050701
• Source Full Name:
  48th Annual Society for Epidemiologic Research (SER) Meeting, June 16-19, 2015, Denver, Colorado
• End Date:
  20250630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:a68594ddb16515b31c9681171b4ce293ef3b958f9c1a3d37d664866afa3a44dade823a84a1012c07b92f834698ec0d0689be768503d2e7853ec3530d5418ca08
• Download URL:
  https://stacks.cdc.gov/view/cdc/212819/cdc_212819_DS1.pdf
• File Type:
  [PDF - 730.50 KB ]